Liver Bio-Kit

Drug-induced liver injury (DILI), a significant concern in pharmaceutical development, continues to pose challenges in understanding due to the limited predictive capability of commonly employed analytical models. For instance, animal models are hindered by species differences in drug toxicity, whereas traditional 2D cell-based systems lack the intricate cellular makeup necessary to predict drug toxicity mechanisms in humans accurately. To circumvent these obstacles, the Emulate Liver-Chip integrates up to four human cell types within a dynamic microenvironment, facilitating human-relevant functionality and drug response. It transcends the constraints of conventional preclinical models and can be employed in various stages of drug discovery and development, including general, mechanistic, and predictive assessments of drug candidate toxicity.

Depending on the requirements of the study, both co-culture and quad-culture configurations of the Liver-Chip are available. Learn more about this technology and how you can predict drug safety and evaluate AAV gene delivery of preclinical candidates with confidence.